|
|
||||||||
J Thorac Cardiovasc Surg 2003;126:875-877
© 2003 The American Association for Thoracic Surgery
Brief communications |
a Department of Pneumology, Hôpital Beaujon, Clichy, France
b Department of Vascular and Thoracic Surgery, Hôpital Beaujon, Clichy, France
Received for publication December 23, 2002; accepted for publication February 11, 2003.
* Address for reprints: Gaëlle Dauriat, MD, Service de Pneumologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, 100 boulevard du Général Leclerc, 92110, Clichy, France
gaelle.dauriat{at}bjn.ap-hop-paris.fr
Chylothorax is a well-known complication after lung transplantation for lymphangioleiomyomatosis. Standard therapeutic options, including dietary regimens containing medium-chain triglycerides, chest tube drainage, and thoracic duct ligation have previously been reported as successful in managing chylothorax in lung transplant recipients with lymphangioleiomyomatosis.1,2
We report a patient with refractory chylothorax after bilateral lung transplantation for lymphangioleiomyomatosis that failed to respond to all conventional therapies. After a 7-month postoperative period of continuous chylous effusion, the injection of povidone (INN polyvidone) through the chest tube was able to stop the chylous effusion definitively and rapidly.
Clinical summary
A 35-year-old woman with end-stage lymphangioleiomyomatosis was referred to our center for lung transplantation (LT). Lymphangioleiomyomatosis had been revealed 6 years before by bilateral pneumothoraces that required bilateral pleurodesis by videothoracoscopy. At admission, the patient was dyspneic at rest, requiring high-flow oxygen supplementation (12 L/min). Computed tomographic scan revealed large cysts (Figure 1). On May 21, 2000, bilateral LT was performed. During the operation, striking dilations of lymphatic vessels located on parietal pleura were observed.
|
|
Discussion
Chylothorax is a well-known complication after single or bilateral LT for lymphangioleiomyomatosis. Among 34 lung transplant recipients with lymphangioleiomyomatosis, Boehler and colleagues1 reported 3 cases of postoperative chylothorax. Chylous effusion resolved in all cases after thoracic duct ligation, thoracotomy associated with medium-chain triglyceride dietary regimen, or needle aspiration. In another series, postoperative chylous fistula was observed in 4 of 12 patients who underwent LT for lymphangioleiomyomatosis.2 Favorable results were obtained in all cases after thoracic duct ligation or sclerosis.2 We report here a case of chylothorax after bilateral LT that was unusual with respect to the massive output of pleural effusion and the long-term course. The large output could be explained by the extreme severity of lymphangioleiomyomatosis before LT.
As previously reported in other cases, the chylorrhea was explained by a leakage of chylous fluid into the mediastinum from dilated and torn lymphatic vessels.1 After a 7-month postoperative period of continuous chylous effusion despite all conventional therapies, the injection of povidone through the chest tube was the only way to stop definitively the chylous effusion.
There is no standardized treatment of chylous effusion because of its infrequent occurrence and various causes. Most authors agree that the first step should be a conservative management with medium-chain triglyceride dietary regimen or total parenteral nutrition in association with chest tube drainage.3 In case of failure of medical management, the thoracic duct can be ligated.3 For refractory chylothorax, three alternative procedures are generally considered: somatostatin administration, pleuroperitoneal shunt, and injection of sclerosing agent (eg, talc, fibrin glue) through the chest tube.3,4 Povidone iodine injection has never been described for the management of chylothorax. Nevertheless, povidone has been reported as effective in the cases of malignant pleural effusions.5. In our case we observed a dramatic efficiency of povidone within the first day after the injection. We hypothesize that povidone may have acted in inducing a true pleurodesis and also as a sclerosing agent on the abnormal lymphatic vessels. This latter hypothesis is suggested by the persistence of moderate stable chylous effusion on both sides in our patient.
In conclusion, our observations suggest that the simplicity of use and the absence of reported side effects with povidone could make it an effective therapy in cases of refractory chylothorax after LT for lymphangioleiomyomatosis.
References
This article has been cited by other articles:
![]() |
N. Shigemura, T. Kawamura, M. Minami, N. Sawabata, M. Inoue, T. Utsumi, T. Nakagiri, G. Matsumiya, Y. Sawa, and M. Okumura Successful factor XIII administration for persistent chylothorax after lung transplantation for lymphangioleiomyomatosis. Ann. Thorac. Surg., September 1, 2009; 88(3): 1003 - 1006. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Rizzardi, M. Loy, G. Marulli, and F. Rea Persistent chylothorax in lymphangioleiomyomatosis treated by intrapleural instillation of povidone. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 214 - 215. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |